CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red ...

-- Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases -- ...

Taipei-based biotech Acepodia announced yesterday (3 September) that it has agreed to a collaboration with Pfizer Ignite, a subsidiary of Pfizer, in which Pfizer’s resources and expertise will be ...

ALAMEDA, Calif. and TAIPEI, Sept. 3, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation ...

Acepodia Inc.’s antibody cell conjugation platform could change the way CAR T-cell therapies are manufactured, clearing the way for an off-the-shelf model to treat numerous cancers that is safer and ...

To adapt to changing environmental pressures, bacteria have developed various methods that allow them to uptake exogenous DNA and incorporate it into their own genomes. One of these processes is ...

Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases Pfizer ...